logo.png
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
April 24, 2023 08:05 ET | GRI Bio, Inc.
LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
April 24, 2023 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its...
logo.jpg
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
April 21, 2023 11:55 ET | Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune...
Logo.png
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
April 19, 2023 08:30 ET | Imunon, Inc.
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE...
Logo.jpg
Biostage Appoints Ron Packard to Board of Directors
April 10, 2023 09:30 ET | Biostage, Inc.
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Logo.jpg
Biostage Announces $6 Million Financing to Advance Clinical Trial
April 06, 2023 09:30 ET | Biostage, Inc.
HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
logo.png
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
March 29, 2023 07:00 ET | BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in...
Logo.png
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
March 23, 2023 08:30 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Logo.png
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
March 22, 2023 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
logo.png
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
February 22, 2023 08:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...